GLI1 and cancer: Although our present knowledge about the impact of HH/GLI on tumor immune evasion is fairly limited, first evidence from preclinical and clinical observations suggests that next-generation HH/GLI inhibitors together with strategies reactivating the antitumoral immune response may represent the next leap for anti-HH/GLI therapy of cancers [154,155,156,157,158].